GlassScriptPhysician profile
Jens J Thiele
NPI 1659562650
$3,431.37
in general payments reported to CMS, 2019-2025
28 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $105 · 2021: $321 · 2022: $538 · 2023: $591 · 2024: $1,122 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.36 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $417.18 | 2019-2024 | |
| Abbvie INC. | $346.03 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $343.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $283.95 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $207.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $204.42 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $190.75 | 2019-2025 | Tremfya |
| Amgen INC. | $170.30 | 2020-2024 | Otezla |
| Dermavant Sciences, INC. | $158.99 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $148.15 | 2024-2025 | Aklief, Nemluvio |
| Organogenesis INC. | $125.53 | 2022 | |
| Lilly USA, LLC | $116.83 | 2019-2024 | Taltz, Zepbound, Olumiant |
| Mimedx Group, INC. | $109.60 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.97 | 2024 | Duobrii, Siliq |
| Leo Pharma INC. | $89.40 | 2023 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $87.64 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $62.98 | 2019-2022 | |
| Dermira, INC. | $62.53 | 2019 | |
| Krystal Biotech INC | $46.49 | 2023 | Vyjuvek |
| Almirall LLC | $41.69 | 2021 | |
| Biofrontera INC. | $33.38 | 2021-2025 | |
| Incyte Corporation | $28.72 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.80 | 2021 | |
| Allergan, INC. | $16.08 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.99 | 2019 | |
| Convatec INC. | $13.68 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jens Thiele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.